Wezlana™ ,
Ustekinumab-auub
(This drug is a biosimilar to Stelara®)
,Limited human data; No adverse effects or risks in animal studies.
No human data.
Common side effects include upper respiratory infections, headache, tiredness, itching, vomiting, vaginal yeast infections, urinary tract infections, redness at the injection site
Rare side effects include risk of serious infections, risk of malignancy, hypersensitivity reactions (anaphylaxis), Posterior Reversible Encephalopathy Syndrome (PRES), and non infectious pneumonia. Wezlana™ is an FDA approved interchangeable biosimilar to Stelara® (ustekinumab).